# US 2015/0031757 A1 · Treating glaucoma, cardiovascular diseases, and renal diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031757 A1
- Document ID: US20150031757A1
- Status: Published application
- Kind: A1
- Application number: 14/510,921
- Filed: 2014-10-09
- Published: 2015-01-29
- Earliest claimed: 2006-04-28
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Eric M. Poeschla; Roman A. Barraza
- Web page: https://patentgrep.com/patent/US20150031757A1

## CPC

- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 38/44: Oxidoreductases (1)
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 35/00: Antineoplastic agents
- C12N 9/0083: {Miscellaneous (1.14.99)}
- C12Y 114/99001: Prostaglandin-endoperoxide synthase (1.14.99.1), i.e. cyclooxygenase
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2799/04: in vivo
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided.

## Claims

### Claim 1

(canceled)

### Claim 2

A method for treating a mammal having glaucoma or elevated intraocular pressure, said method comprising administering nucleic acid encoding a polypeptide having cyclooxygenase-2 activity to an eye of said mammal under conditions effective to reduce intraocular pressure of said eye by at least 10 percent.

### Claim 3 (depends on 2)

The method of claim 2, wherein said mammal is a human.

### Claim 4 (depends on 2)

The method of claim 2, wherein said administering step comprises contacting said eye with a solution containing said nucleic acid encoding said polypeptide having cyclooxygenase-2 activity.

### Claim 5 (depends on 2)

The method of claim 2, wherein said method is effective to reduce said intraocular pressure by at least 20 percent.

### Claim 6 (depends on 2)

The method of claim 2, wherein said method is effective to reduce said intraocular pressure by at least 30 percent.

### Claim 7 (depends on 2)

The method of claim 2, wherein said nucleic acid encoding said polypeptide having cyclooxygenase-2 activity is administered using a viral vector.

### Claim 8 (depends on 7)

The method of claim 7, wherein said viral vector is a lentiviral vector.

### Claim 9 (depends on 2)

The method of claim 2, wherein said polypeptide having cyclooxygenase-2 activity is a human cyclooxygenase-2 polypeptide, and wherein said nucleic acid encoding said polypeptide having cyclooxygenase-2 activity is codon-optimized for use in mammalian cells.
